secwatch.observer — SEC 8-K summary
======================================

Issuer:     TAO Synergies Inc. (TAOX)
CIK:        0001571934
Form:       8-K
Filed at:   2024-12-20T23:59:59+00:00
Accession:  0001104659-24-130537
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synaptogenix forms special committee to explore strategic alternatives; ends Bryostatin-1 MS trial
--------------------------------------------------------------------------------

- Board formed special committee to explore strategic opportunities; $19.6M cash and ~1.3M shares outstanding as of Sept 30, 2024.
- Terminated Phase 1 trial of Bryostatin-1 in multiple sclerosis due to slow enrollment.
- CEO Alan Tuchman's base salary reduced to $12,500/month effective Jan 1, 2025.
- President/CSO Daniel Alkon consulting fee reduced to $16,000/month under new agreement.
- Company expects dramatic cash burn decline; submitted NIH grant proposal for Bryostatin-1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1571934/000110465924130537/0001104659-24-130537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1571934/000110465924130537/tm2431397d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-130537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer